Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
100% free, unsubscribe anytime.
GRAIL's multi-cancer test PMA filed • Formation's $500M autoimmune buy • RFK Jr. revamps Alzheimer's priorities • Oracle's AI data launch
Cell therapy manufacturing pivots to scale, Quadruplet myeloma becomes standard, AAV safety pressure rises
UnitedHealth crashes on MA rate shock & guidance cut; Intellia clears partial CRISPR hold; Resonetics M&A and Boston Scientific updates inside.
Sarepta’s 3-year durability resets gene therapy risk, UnitedHealth earnings frame utilization pressure, FDA tightens MRD expectations.
Why milestone-heavy deals, AI workflows, and payer rules now shape execution risk.
Janux secures $850M BMS deal; Corxel raises $287M for oral obesity; Mendra launches with $82M.
